Conflicts of interest (COI) & CRO belong to the pharmaceutical Company (CRO b2Ph [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2022-07-08 12:23 (629 d 23:16 ago) – Posting: # 23115
Views: 2,099

Dear Osama!

❝ But let us return to the main topic, should the regulatory authorities refuse the submission and acceptance of BE studies that have been performed in a CRO belonging to the sponsor? are there any references? or are there other opinions other than that?

Unless study trend/result is too much doubtful, regulatory bodies generally does not refuse for submission and acceptance. I believe as a sponsor, the submission of all the studies including failed one is important during such time as it gives impression that sponsor has appropriate formulation which are BE to RLD.

Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
117 visitors (0 registered, 117 guests [including 8 identified bots]).
Forum time: 10:40 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5